Table 3.
Simulation study results for the three dose-range methods, linear, allometry and maturation adjustment (LA, AA, MA) under several scenarios.
| Method | Linear adjustment |
Allometry adjustment |
Maturation adjustment |
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose (mg/kg) | 25 | 35 | 45 | 55 | 70 | SR | AD | 35 | 50 | 65 | 80 | 100 | SR | AD | 30 | 45 | 55 | 70 | 85 | SR | AD |
| Scenario 1 | |||||||||||||||||||||
| WM1-bCRM | 0 | 0 | 0.3 | 7.8 | 81.8 | 10.1 | 89.6 | 0 | 1.4 | 39.6 | 56.8 | 2.1 | 0.1 | 96.4 | 0 | 0.1 | 8.2 | 60.4 | 30 | 1.3 | 90.4 |
| WAIC-bCRM | 0 | 0 | 0.2 | 8.1 | 81.7 | 10 | 89.8 | 0 | 1.2 | 37.2 | 59.1 | 2.3 | 0.2 | 96.3 | 0 | 0.3 | 6.3 | 53.4 | 38.3 | 1.7 | 91.7 |
| AP ESS-bCRM | 0 | 0 | 0 | 14.4 | 77.9 | 6.2 | 92.2 | 0 | 1.4 | 50.9 | 45.2 | 2.2 | 0.2 | 96.1 | 0 | 0.2 | 12.2 | 59.5 | 26.8 | 1 | 86.2 |
| AP LIP-bCRM | 0 | 0 | 0.1 | 13.9 | 77.1 | 7.1 | 91 | 0 | 1.1 | 35.1 | 59.8 | 3.9 | 0.1 | 94.9 | 0 | 0.1 | 7.3 | 58.3 | 32.3 | 2 | 90.6 |
| Scenario 2 | |||||||||||||||||||||
| WM1-bCRM | 0 | 0 | 0.2 | 51.8 | 48 | 0 | 48 | 0 | 6.9 | 92.7 | 0.4 | 0 | 0 | 92.7 | 0 | 0 | 53 | 47 | 0 | 0 | 47 |
| WAIC-bCRM | 0 | 0 | 0.2 | 44.9 | 54.8 | 0.1 | 54.8 | 0 | 7.9 | 91.7 | 0.3 | 0 | 0.1 | 91.7 | 0 | 0.1 | 41.7 | 58.1 | 0 | 0.1 | 58.1 |
| AP ESS-bCRM | 0 | 0 | 0 | 53 | 47 | 0 | 47 | 0 | 8 | 91.8 | 0.2 | 0 | 0 | 91.8 | 0 | 0.1 | 62.6 | 37.1 | 0.1 | 0 | 37.1 |
| AP LIP-bCRM | 0 | 0 | 0 | 51 | 49 | 0 | 49 | 0 | 7.8 | 91.6 | 0.6 | 0 | 0 | 91.6 | 0 | 0 | 52.6 | 47.4 | 0 | 0 | 47.4 |
| Scenario 3 | |||||||||||||||||||||
| WM1-bCRM | 0 | 0.2 | 18.7 | 80.1 | 0.9 | 0.1 | 98.8 | 1 | 86.6 | 12 | 0 | 0 | 0.4 | 86.6 | 0 | 18.7 | 79.6 | 1.5 | 0 | 0.2 | 98.3 |
| WAIC-bCRM | 0 | 0.2 | 26.2 | 72 | 1.6 | 0 | 98.2 | 1.3 | 88.1 | 10.2 | 0 | 0 | 0.4 | 88.1 | 0 | 25.4 | 73.5 | 1.1 | 0 | 0 | 98.9 |
| AP ESS-bCRM | 0 | 0.4 | 26.1 | 73 | 0.5 | 0 | 99.1 | 1.2 | 89 | 9.5 | 0 | 0 | 0.2 | 89 | 0.1 | 27 | 71.9 | 1 | 0 | 0 | 98.9 |
| AP LIP-bCRM | 0 | 0.1 | 24.9 | 74.2 | 0.8 | 0 | 99.1 | 0.6 | 83.6 | 14.6 | 0 | 0 | 0.9 | 83.6 | 0.4 | 22 | 77.1 | 0.4 | 0 | 0.1 | 99.1 |
| Scenario 4 | |||||||||||||||||||||
| WM1-bCRM | 0 | 0 | 1.3 | 61.8 | 36.9 | 0 | 61.8 | 0.1 | 23.5 | 75.2 | 1.2 | 0 | 0 | 75.2 | 0 | 1.2 | 56.3 | 42.4 | 0 | 0.1 | 56.3 |
| WAIC-bCRM | 0 | 0 | 4.3 | 64.7 | 31 | 0 | 64.7 | 0.2 | 28.5 | 70.5 | 0.7 | 0 | 0.1 | 70.5 | 0 | 3.4 | 63.5 | 33 | 0 | 0.1 | 63.5 |
| APESS-bCRM | 0 | 0 | 3.2 | 73.4 | 23.4 | 0 | 73.4 | 0 | 35.4 | 63.9 | 0.4 | 0 | 0.3 | 63.9 | 0 | 2.8 | 69.8 | 27.4 | 0 | 0.1 | 69.8 |
| APLIP-bCRM | 0 | 0 | 2.5 | 68.2 | 29.2 | 0 | 68.2 | 0 | 25.1 | 73.6 | 0.6 | 0 | 0.5 | 73.6 | 0 | 1.1 | 61.1 | 37.5 | 0.1 | 0.1 | 61.1 |
| Scenario 5 | |||||||||||||||||||||
| WM1-bCRM | 0.9 | 20.7 | 61.5 | 15.9 | 0 | 1 | 61.5 | 32.5 | 59.7 | 0.4 | 0 | 0 | 7.4 | 59.7 | 10.9 | 72.2 | 14.5 | 0 | 0 | 2.4 | 72.2 |
| WAIC-bCRM | 0.1 | 18.2 | 68 | 13 | 0 | 0.7 | 68 | 36.4 | 56.7 | 0.6 | 0 | 0 | 6.3 | 56.7 | 13 | 70.9 | 13.7 | 0 | 0 | 2.4 | 70.9 |
| APESS-bCRM | 0.7 | 21.9 | 65.3 | 11.7 | 0 | 0.4 | 65.3 | 40.2 | 53.8 | 0.2 | 0 | 0 | 5.8 | 53.8 | 13.4 | 72.7 | 12.5 | 0 | 0 | 1.4 | 72.7 |
| APLIP-bCRM | 0.4 | 22.5 | 62.2 | 14.8 | 0 | 0.1 | 62.2 | 33.2 | 57.7 | 0.4 | 0 | 0 | 8.7 | 57.7 | 11.7 | 72.1 | 13.1 | 0 | 0 | 3.1 | 72.1 |
| Scenario 6 | |||||||||||||||||||||
| WM1-bCRM | 0 | 0 | 0 | 2.8 | 96 | 1.2 | 96 | 0 | 0 | 90.4 | 9.6 | 0 | 0 | 90.4 | 0 | 0 | 3.7 | 96.2 | 0.1 | 0 | 96.2 |
| WAIC-bCRM | 0 | 0 | 0 | 6 | 93.2 | 0.8 | 93.2 | 0 | 0 | 94.6 | 5.4 | 0 | 0 | 94.6 | 0 | 0 | 5.5 | 93.7 | 0.8 | 0 | 93.7 |
| APESS-bCRM | 0 | 0 | 0 | 7.9 | 90.1 | 2 | 90.1 | 0 | 0.1 | 92.4 | 7.5 | 0 | 0 | 92.4 | 0 | 0 | 5.7 | 94.3 | 0 | 0 | 94.3 |
| APLIP-bCRM | 0 | 0 | 0 | 5.6 | 93.4 | 1 | 93.4 | 0 | 0 | 87.8 | 12.2 | 0 | 0 | 87.8 | 0 | 0 | 4 | 95.6 | 0.4 | 0 | 95.6 |
Note: The percentage of correct selection (PCS) are represented in italic, that is, the sMSD. The percentage of acceptable dose (underlined) are summed up in bold. The simulation setting for each approach are given in Table 1.